JP2003535029A5 - - Google Patents

Download PDF

Info

Publication number
JP2003535029A5
JP2003535029A5 JP2001519893A JP2001519893A JP2003535029A5 JP 2003535029 A5 JP2003535029 A5 JP 2003535029A5 JP 2001519893 A JP2001519893 A JP 2001519893A JP 2001519893 A JP2001519893 A JP 2001519893A JP 2003535029 A5 JP2003535029 A5 JP 2003535029A5
Authority
JP
Japan
Prior art keywords
antiprogestins
endometriosis
uterine
miferistone
endometnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001519893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535029A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/023770 external-priority patent/WO2001015679A2/en
Publication of JP2003535029A publication Critical patent/JP2003535029A/ja
Publication of JP2003535029A5 publication Critical patent/JP2003535029A5/ja
Pending legal-status Critical Current

Links

Images

JP2001519893A 1999-08-31 2000-08-31 良性ホルモン依存性婦人科疾患の治療及び予防のためのメソプロゲスチン（プロゲステロン受容体モジュレーター） Pending JP2003535029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31
US06/266,323 1999-08-31
PCT/US2000/023770 WO2001015679A2 (en) 1999-08-31 2000-08-31 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders

Publications (2)

Publication Number Publication Date
JP2003535029A JP2003535029A (ja) 2003-11-25
JP2003535029A5 true JP2003535029A5 (https=) 2009-07-16

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001519893A Pending JP2003535029A (ja) 1999-08-31 2000-08-31 良性ホルモン依存性婦人科疾患の治療及び予防のためのメソプロゲスチン（プロゲステロン受容体モジュレーター）

Country Status (34)

Country Link
EP (1) EP1229906B1 (https=)
JP (1) JP2003535029A (https=)
KR (3) KR20080066095A (https=)
AR (1) AR025457A1 (https=)
AT (1) ATE375160T1 (https=)
AU (1) AU781840B2 (https=)
BG (1) BG65817B1 (https=)
BR (1) BR0014161A (https=)
CA (1) CA2382580C (https=)
CO (1) CO5200772A1 (https=)
CZ (1) CZ2002704A3 (https=)
DE (1) DE60036723T2 (https=)
DK (1) DK1229906T3 (https=)
EA (1) EA007854B1 (https=)
EE (1) EE05172B1 (https=)
ES (1) ES2295050T3 (https=)
HR (1) HRP20020267A2 (https=)
HU (1) HUP0202429A3 (https=)
IL (1) IL148416A0 (https=)
LT (1) LT5034B (https=)
LV (1) LV12941B (https=)
ME (1) MEP13808A (https=)
MX (1) MXPA02002191A (https=)
NO (1) NO20020999L (https=)
NZ (1) NZ517471A (https=)
PE (1) PE20010578A1 (https=)
PL (1) PL198790B1 (https=)
PT (1) PT1229906E (https=)
RO (1) RO122179B1 (https=)
RS (1) RS50283B (https=)
SI (1) SI20852B (https=)
SK (1) SK287192B6 (https=)
UA (1) UA78184C2 (https=)
WO (1) WO2001015679A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255355A1 (en) * 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
JP4709328B2 (ja) * 2009-06-17 2011-06-22 国立大学法人 熊本大学 月経困難症の予防及び／又は治療薬
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
EP1043325B1 (en) * 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
UA37259C2 (uk) 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (en) * 1999-01-14 2001-10-17 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
HK1043788A1 (zh) * 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法

Similar Documents

Publication Publication Date Title
Coukell et al. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
Junge et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study
Haria et al. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders
TR200001942T2 (tr) Opioid agonist/antagonist kombinasyonlar
JP2003535029A5 (https=)
US20120015917A1 (en) Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy
TNSN01068A1 (fr) Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif
KR970704451A (ko) 기능부전성 자궁출혈 치료용 약제의 제조에 유용한 프로게스테론 길항제(Progesterone Antagonists Useful for Preparing Medicaments for Treating Dysfunctional Uterine Bleeding)
TNSN00183A1 (fr) COMPOSITIONS COMPRENANT LE POLYPEPTIDE IL-1ra ET UN INHIBITEUR DE MATURATION ET DE LIBERATION DE IL-1 ET METHODES DE TRAITEMENT LES UTILISANT
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
TNSN04001A1 (fr) Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase.
JP2007535519A5 (https=)
JP2010539153A5 (https=)
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
EA200100799A1 (ru) Антагонисты фактора опухолевого некроза и их применение при эндометриозе
JP2004500325A5 (https=)
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
CO5580789A2 (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis
MEP13808A (en) Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
BR0005318A (pt) Utilização de inibidores de secreção da apo b/mtp e agentes antiobesidade
CL2011000283A1 (es) Preparado combinado polifasico que comprende 4 fases con unidades de dosis que contienen primera : <3 mg de estradiol (et), segunda: unas con <2 mg de et y 2 mg de dienogest (dg) y otras con <2 mg de et y 3 mg de dg, tercera: <1 mg de et y cuarta: placebo; util para la anticoncepcion oral y tratar para la hemorragia uterina disfuncional.
JP2003522795A5 (https=)
CN1436081A (zh) 低剂量口服避孕药启动试剂盒
Akat et al. Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension
NO20072687L (no) Farmasoytisk prevensjonspreparat